ClinicalTrials.gg

Program

BP102

Also written as “SHR-1701、 BP102 、XELOX”, “SHR-1701;BP102” and “FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Lung Neoplasms · Colorectal Neoplasms · Uterine Cervical Neoplasms, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Apr 19, 20217 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine72 open or runningphase 3since Apr 19, 2021Apr 19, 2021Dec 2026phase 2 · NCT06915142

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 19, 2021First study: phase 3 study in Colorectal NeoplasmsFirst studyNCT04856787 · 62 enrolled · China
  2. Apr 19, 2021Phase 2 study in Advanced Solid TumorsNCT04856774 · 81 enrolled · China
  3. Jul 16, 2021Phase 2 study in Advanced or Metastatic Non-squamous Non-small Cell Lung CancerNCT04974957 · 71 enrolled
  4. Oct 14, 2021Phase 3 study in Uterine Cervical NeoplasmsNCT05179239 · 31 enrolled · China
  5. Dec 23, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05169801 · 520 enrolled · China
  6. Apr 1, 2025Phase 2 study in Advanced Malignant TumourNCT06915142 · 300 planned · China
  7. Nov 14, 2025Phase 2 study in Lung NeoplasmsNCT07241767 · 200 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Advanced Malignant TumourNCT06915142
  2. Nov 2027Primary completion: phase 2 study in Lung NeoplasmsNCT07241767

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07241767Lung Neoplasms · China2RecruitingNov 2027200
NCT06915142Advanced Malignant Tumour · China2RecruitingDec 2026300
NCT05169801Carcinoma, Non-Small-Cell Lung · China3CompletedOct 21, 2019520
NCT05179239Uterine Cervical Neoplasms · China3TerminatedAug 12, 202431
NCT04974957Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer2UNKNOWNFeb 28, 202271
NCT04856787Colorectal Neoplasms · China3TerminatedApr 17, 202462
NCT04856774Advanced Solid Tumors · China2CompletedMar 30, 202481

How it is read

Names in the registry

  • “SHR-1701、 BP102 、XELOX”, 2 entries
  • “SHR-1701;BP102”, 2 entries
  • “FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin”, 1 entry
  • “FH-006 ; SHR-1316 ; BP102”, 1 entry
  • “HRS-7058 + BP102”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.